{"id":"low-dose-combination-polydiuretic-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Electrolyte imbalance"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Low-dose combination polydiuretic therapy typically combines agents from different diuretic classes (such as thiazides, potassium-sparing diuretics, and loop diuretics) at sub-therapeutic individual doses. By using lower doses of multiple agents with complementary mechanisms, the approach aims to achieve additive blood pressure reduction while reducing adverse effects like hypokalemia and metabolic derangements that occur at higher single-agent doses.","oneSentence":"A fixed-dose combination of multiple diuretics at reduced individual doses that work synergistically to reduce blood pressure and fluid retention while minimizing electrolyte disturbances.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:11.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension management"},{"name":"Fluid overload and edema reduction"}]},"trialDetails":[{"nctId":"NCT05129722","phase":"PHASE4","title":"Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial","status":"TERMINATED","sponsor":"The George Institute","startDate":"2022-10-01","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eplerenone (inspra), Bumetanide (Burinex) and Empagliflozin (jardiance)"],"phase":"marketed","status":"active","brandName":"Low dose combination polydiuretic therapy","genericName":"Low dose combination polydiuretic therapy","companyName":"The George Institute","companyId":"the-george-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A fixed-dose combination of multiple diuretics at reduced individual doses that work synergistically to reduce blood pressure and fluid retention while minimizing electrolyte disturbances. Used for Hypertension management, Fluid overload and edema reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}